Day-4 antipseudomonal and anti-MRSA de-escalation was not associated with higher mortality in critically ill patients with sepsis

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Background Broad empiric antibiotics are often appropriate at the start of intensive care unit (ICU) sepsis care; however, continued antipseudomonal or anti-methicillin-resistant Staphylococcus aureus (MRSA) coverage may no longer be justified by the day-4 reassessment. We examined antibiotic de-escalation at this clinical decision point. Materials and methods We emulated two parallel target trials in Medical Information Mart for Intensive Care IV (MIMIC-IV) v3.1 and conducted a supportive multicenter analysis in the eICU Collaborative Research Database (eICU-CRD) v2.0. The strict MIMIC-IV cohort included patients with ICU sepsis, early receipt of broad-spectrum antibiotics, survival and continued observation through 96 h, available culture information before time zero, no recorded multidrug-resistant organism evidence, and no prespecified exclusions. Time zero was 72 h after antibiotic initiation; exposure was classified during 72–96 h, and follow-up began at 96 h. Trial A compared anti-MRSA de-escalation with continuation, and Trial B compared antipseudomonal de-escalation with continuation. Propensity scores, overlap weighting, and bootstrap confidence intervals were used. Results The strict MIMIC-IV cohort included 5,762 patients. In Trial B, 1,569 patients were de-escalated, and 3,070 continued antipseudomonal coverage. De-escalation was associated with lower 30-day mortality (24.1% vs. 29.0%; risk difference, −4.91 percentage points; 95% confidence interval, −7.27 to −2.23), lower in-hospital death, lower stage 2–3 acute kidney injury, and more death-adjusted antibiotic-free days. In Trial A, 3,041 patients were de-escalated, and 1,728 continued anti-MRSA coverage; there was no evidence of higher 30-day mortality (26.3% vs. 27.8%; risk difference, −1.44 percentage points; 95% confidence interval, −3.75 to 1.11), and de-escalation was associated with more antibiotic-free days. In eICU-CRD, Trial B showed a directionally consistent association with lower hospital mortality (10.2% vs. 12.7%; cluster-bootstrap risk difference, −2.42 percentage points; 95% confidence interval, −3.87 to −0.87). Conclusion Day-4 de-escalation was not associated with higher mortality and was accompanied by reduced antibiotic exposure. The lower mortality and kidney-injury estimates in Trial B are exploratory because de-escalation may mark early recovery that is incompletely captured in structured data. The eICU-CRD analysis provides directional support rather than formal external validation. Prospective evaluation is warranted.